Results 231 to 240 of about 37,916 (265)

Tumor‐Specific Delivery of CD28 siRNA via Lyso‐PC C‐16 Modified Lipid Nanoparticles Overcomes Anti‐PD‐1 Resistance by Remodeling Tumor Microenvironment

Advanced Science, EarlyView.
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai, Keyu Wang, Jiali Fang, Shaorui Jia, Yansong Shi, Wanfeng Gao, Xinpeng Liu, Jiaqiang Li, Zenghui Cui, Yazhi Qian, Xiaosu Chen, Dan Ding, Xuetao Cao   +12 more
wiley   +1 more source

Orchestration of the tumor microenvironment by citrus flavonoids: from preclinical mechanisms to translational therapeutic. [PDF]

Front Immunol
Ma S, Wang X, Li M, Wang W, Ren Y, Shen Y, Yang K, Zhang Z, Feng Z, Tang S.   +9 more
europepmc   +1 more source

Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor

Advanced Science, EarlyView.
The study characterizes C36, a highly selective EZH2/PRC2 inhibitor that acts via a novel allosteric mechanism. Unlike previous inhibitors, C36 inhibits EZH2/PRC2 by disrupting the allosteric communication between EZH2 and EED in a SAM‐noncompetitive manner.
Ting Cao, Dongdong Liu, Haishan Gao, Chenyang Qin, Wen Zhang, Ziyun Lu, Dongxia Tan, Yuxiu Qu, Yusong Liu, Zhiran Zou, Hongtao Yu, Wei Qi   +11 more
wiley   +1 more source

A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. [PDF]

Pharmaceuticals (Basel)
Zhang Z, Zong H, Li Z, Wang S, Xiao X, Xie Y, Zhu J.   +6 more
europepmc   +1 more source

Parthenolide inhibits the progression of intrahepatic cholangiocarcinoma by promoting ferroptosis through inhibiting UBD. [PDF]

Cancer Biol Ther
Xie Y, Wang J, Zhou J, Peng Y, Wang Y, Wang Y, Song Y.   +6 more
europepmc   +1 more source

Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer. [PDF]

Nat Immunol
Dong H, Ray A, Rotter LK, Wang J, Grabski I, Mewada H, Wang L, Huang K, Tian Y, Meylan M, Barlow G, Yu C, Raundhal M, Yoon SH, Nakhawa S, Ding L, Zhao JJ, Matulonis UA, Foretz M, Wucherpfennig KW, Irizarry RA, Wein MN, Glimcher LH.   +22 more
europepmc   +1 more source

Synthesis and biological evaluation, network pharmacology, and molecular docking of 2-benzylidene-1-indanone derivatives as antitumor agents. [PDF]

Sci Rep
Liao X, Zhuang R, Zhuang T, Xie M, Zhou B.   +4 more
europepmc   +1 more source

Roles of lactate and lactylation in tumor immune suppression and drug resistance. [PDF]

Front Immunol
Li J, Yang W, Xin T, Zhou Z, Liu X, Tang P, An J, Ma B, Peng F.   +8 more
europepmc   +1 more source